Yuxiang (Henry) Zhao
About Yuxiang (Henry) Zhao
Yuxiang (Henry) Zhao is a scientist at Bristol Myers Squibb in Massachusetts, United States, with a background in pharmaceutical sciences and extensive research experience.
Current Position at Bristol Myers Squibb
Yuxiang (Henry) Zhao currently works as a Scientist at Bristol Myers Squibb in Massachusetts, United States. In his role, he supports the digital transformation of platform analysis for process development. His work involves investigating potential applications of innovative process analytical technology within bio-manufacturing.
Previous Experience at Sanofi
In 2020, Yuxiang Zhao interned at Sanofi in Framingham, Massachusetts, United States for five months. During his internship, he engaged in various projects and gained valuable experience in the pharmaceutical industry.
Educational Background
Yuxiang Zhao has a rich educational background. He completed his Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences from Duquesne University, where he studied from 2014 to 2020. He earned his Master of Science (M.S.) in Medical Research and Technology from the University of Maryland, Baltimore, from 2012 to 2014. Additionally, Zhao completed a Bachelor's degree in Pharmaceutical Sciences from Wuhan University between 2006 and 2010.
Research and Academic Experience
Yuxiang Zhao has extensive research experience. He worked as a Research Associate at the Life and Science Institute, Wuhan University, from 2011 to 2012. Before that, he was a Research Assistant at the Department of Pharmaceutical Science, Friedrich-Schiller-Universität in Jena, Thuringia, Germany, from 2009 to 2010. These roles provided him with a solid foundation in pharmaceutical science research.
Technical Expertise and Innovations
Yuxiang Zhao is known for developing FTIR calibration methods specifically for downstream biopharmaceutical process monitoring. He also explores the potential applications of innovative process analytical technology in bio-manufacturing. His technical expertise supports the digital transformation initiatives for process development at Bristol Myers Squibb.